Abstract:A bstract Motivation Lung cancer is a chronic non-communicable disease and is the cancer with the world’s highest incidence in the 21 st century. One of the leading mechanisms underlying the development of lung cancer in nonsmokers is an amplification of the epidermal growth factor receptor (EGFR) gene. However, laboratories employing conventional processes of drug discovery and development for such targets encounter several pain-points that are cost- and time-consuming. Moreover, high failure rates are caused by efficacy and safety problems during research and development. Therefore, it is imperative to develop improved methods for drug discovery. Herein, we developed a deep learning model with spatial graph embedding and molecular descriptors based on predicting pIC 50 potency estimates of small molecules and classifying hit compounds against the human epidermal growth factor receptor (LigEGFR). The model was generated with a large-scale cell line-based dataset containing broad lists of chemical features. Results LigEGFR outperformed baseline machine learning models for predicting pIC 50 . Our model was notable for higher performance in hit compound classification, compared to molecular docking and machine learning approaches. The proposed predictive model provides a powerful strategy that potentially helps researchers overcome major challenges in drug discovery and development processes, leading to a reduction of failure to discover novel hit compounds. Availability We provide an online prediction platform and the source code that are freely available at https://ligegfr.vistec.ist , and https://github.com/scads-biochem/LigEGFR , respectively. Key points LigEGFR is a regression model for predicting pIC 50 that was developed for the human EGFR target. It can also be applied to hit compound classification (pIC 50 ≥ 6) and has a higher performance than baseline machine learning algorithms and molecular docking approaches. Our spatial graph embedding and molecular descriptors based approach notably exhibited a high performance in predicting pIC 50 of small molecules against human EGFR. Non-hashed and hashed molecular descriptors were revealed to have the highest predictive performance by using in a convolutional layers and a fully connected layers, respectively. Our model used a large-scale and non-redundant dataset to enhance the diversity of the small molecules. The model showed robustness and reliability, which was evaluated by y-randomization and applicability domain analysis (ADAN), respectively. We developed a user-friendly online platform to predict pIC 50 of small molecules and classify the hit compounds for the drug discovery process of the EGFR target.

LigEGFR: Spatial graph embedding and molecular descriptors assisted bioactivity prediction of ligand molecules for epidermal growth factor receptor on a cell line-based dataset

GraphEGFR: Multi‐task and transfer learning based on molecular graph attention mechanism and fingerprints improving inhibitor bioactivity prediction for EGFR family proteins on data scarcity

Machine learning based personalized drug response prediction for lung cancer patients

In-silico screening of inhibitor on protein epidermal growth factor receptor (EGFR)

Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer

Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer

Prediction of Epidermal Growth Factor Receptor Mutation Subtypes in Non-Small Cell Lung Cancer From Hematoxylin and Eosin-Stained Slides Using Deep Learning

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC-MS, network Pharmacology, Docking, and molecular dynamics

Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches

Deep learning for predicting epidermal growth factor receptor mutations of non-small cell lung cancer on PET/CT images

Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach

Generative AI for Drug Discovery: A GPT-2 and LSTM Based Models for Designing EGFR Inhibitors

FGFR1Pred: an artificial intelligence-based model for predicting fibroblast growth factor receptor 1 inhibitor

Screening of BindingDB database ligands against EGFR, HER2, Estrogen, Progesterone and NF-κB receptors based on machine learning and molecular docking

Precise modelling and interpretation of bioactivities of ligands targeting G protein-coupled receptors.

Development and evaluation of a deep learning model for protein-ligand binding affinity prediction

In silico Identification of Peptide as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Treatment

Predicting epidermal growth factor receptor mutation status of lung adenocarcinoma based on PET/CT images using deep learning

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R